Back to results
US 2020/0061003 A1Published application
Acamprosate formulations, methods of using the same, and combinations comprising the same
AssigneeSynchroneuron, LLC
InventorsBarry S. Fogel, William D. Kerns
Life of this patent
Estimating the term…
Abstract
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
Claims21
1-66. (canceled)
A tablet composition comprising:
- a polymer matrix comprised of at least one polymer, wherein the at least one polymer comprises a carbomer;
- a dose of prazosin dispersed within the polymer matrix, the dose being within a range of about 1.0 mg to about 15 mg;
- and
- a dose of acamprosate dispersed within the polymer matrix, wherein:
- the dose of acamprosate is within a range of about 400 mg to about 1500 mg;
- or
- the acamprosate is present at a level that is about 20% to about 90% of the total weight of the composition;
- and
- optionally at least one pharmaceutically acceptable excipient.
6 more elements
A method comprising a step of
- administering to a subject suffering from or susceptible to an anxiety disorder, PTSD, or panic disorder, a combination of prazosin therapy and acamprosate therapy.
A tablet composition comprising:
- a dose of acamprosate, that is (i) less than 1 g;
- and (ii) distributed within a polymer matrix that comprises a carbomer homopolymer type A;
- and
- optionally at least one pharmaceutically acceptable excipient.
1 more element
Dependencies are inferred from the claim text.